What does the future look like if pull incentives to support antibiotic R&D are insufficient?
HTML-код
- Опубликовано: 26 авг 2024
- AMR Discussion webinar, broadcast on 27 February 2024:
This webinar discusses potential solutions, including support for non-profit R&D organizations, to get new treatments to patients in the scenario of inadequate investment in industry R&D i.e., few or no additional ‘pull’ investments, or ‘pull incentives’ that do not meet industry expectations as to the size of the reward.
It examines the benefits and drawbacks of other solutions to pay for antibiotic R&D, how governments can collaborate to sustain such approaches, and the role of these potential solutions in the long term.
Speakers:
- Radha Rangarajan, Director, CSIR-Central Drug Research Institute, Lucknow (India)
- Aaron S. Kesselheim, Professor of Medicine, Brigham and Women’s Hospital/Harvard Medical School (USA)
- Henry Skinner, Chief Executive Officer, AMR Action Fund (USA)
Moderator: Laura Jung, Medical doctor & AMR researcher, Leipzig University Medical Center, Division of Infectious Diseases and Tropical Medicine, Leipzig (Germany)
REVIVE: revive.gardp.org/
GARDP: www.gardp.org/